Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 6.38M | $29.0M | 8.12% | +5.13M | 2026-06-30 |
| BlackRock, Inc. | 5.74M | $26.0M | 7.30% | +628.6K | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 5.00M | $23.0M | 6.36% | -- | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 4.82M | $22.0M | 6.14% | +400.0K | 2026-06-30 |
| STATE STREET CORP | 4.35M | $20.0M | 5.54% | +786.5K | 2026-06-30 |
| Vestal Point Capital, LP | 4.32M | $20.0M | 5.49% | -155.0K | 2026-06-30 |
| Paradigm Biocapital Advisors LP | 4.18M | $19.0M | 5.31% | -2.01M | 2026-06-30 |
| Jupiter Topco LLC | 3.95M | $18.0M | 5.03% | -- | 2026-06-30 |
| ORBIMED ADVISORS LLC | 3.95M | $18.0M | 5.02% | +345.4K | 2026-06-30 |
| CITADEL ADVISORS LLC | 3.90M | $18.0M | 4.96% | +52.9K | 2026-06-30 |
